Natera Inc Stock Price, News & Analysis

Natera (NASDAQ: NTRA) will expand its Fetal Focus single-gene NIPT from the initial 5-gene panel to a 20-gene panel, with the expanded test launching in Q4 2025. The assay uses Natera's LinkedSNP™ technology to detect challenging homozygous fetal mutations from maternal cfDNA.

Anecdotally, Fetal Focus identified a pregnancy homozygous for the delta F508 cystic fibrosis mutation that another laboratory missed. Natera initiated the prospective EXPAND trial in 2023; EXPAND has enrolled approximately 1,700 patients with genetic confirmation of all outcomes and reported an initial readout where Fetal Focus identified 5 of 5 homozygous cases.

Natera (NASDAQ: NTRA) will release its third quarter 2025 financial results for the period ended September 30, 2025 after market close on November 6, 2025. The company will host a conference call and webcast the same day at 4:30 p.m. ET. Live dial-in numbers and a conference ID are provided, and a webcast replay will be available at the company's investor website.

• Event: Third Quarter 2025 Financial Results
• Date & Time: November 6, 2025 at 4:30 p.m. ET
• Webcast: https://events.q4inc.com/attendee/822764987

Natera (NASDAQ: NTRA) reported prospective PROCEED-CRC trial results for detection of advanced adenomas (AA) from ~1,400 cases collected before the cutoff date.

The analysis included 92 sequential AA samples and 366 normal controls, showing AA sensitivity 22.5% (95% CI: 15.4%–32.4%) and specificity 91.5% (95% CI: 88.2%–93.9%). Adjusting for subtype prevalences from two recent FDA-enabling trials produced sensitivities of 22.4% and 23.7%. Most AA lesions were small: 98.9% <30 mm and 93.5% <20 mm. Results follow earlier CRC case-control performance of 95% sensitivity and 91% specificity. Findings support confidence ahead of the ongoing FIND FDA-grade validation trial initiated in 2025.

Natera (NASDAQ: NTRA) reported phase 3 IMvigor011 results in muscle-invasive bladder cancer showing Signatera-guided adjuvant therapy with atezolizumab improved outcomes versus placebo.

Key findings: 761 patients surveilled, ~half tested Signatera-positive and 250 were randomized. Signatera-positive patients on atezolizumab had median DFS 9.9 vs 4.8 months (HR 0.64; P=0.005) and median OS 32.8 vs 21.1 months (HR 0.59; P=0.01). Persistently Signatera-negative patients avoided adjuvant therapy with DFS 95.4% at 1 year and 88.4% at 2 years. Data will support a premarket approval filing to FDA for Signatera as a companion diagnostic.

Natera (NASDAQ: NTRA) was named to Fast Company’s 2025 Next Big Things in Tech list on October 16, 2025, recognized for its Signatera personalized molecular residual disease (MRD) test.

Signatera is a custom blood test that uses circulating tumor DNA to detect and quantify residual cancer, with clinical validation across multiple cancer types, >140 peer‑reviewed papers, and current ordering by more than 50% of U.S. oncologists. Fast Company selected Signatera as one of five honorees in the health and medicine category for its potential to impact cancer detection, monitoring, and treatment decisions.

Natera (NASDAQ: NTRA) will host an investor conference call and webcast on Oct 23, 2025 at 5:00 a.m. PT (8:00 a.m. ET) to discuss muscle-invasive bladder cancer data being presented at ESMO.

The discussion will cover results from the randomized phase 3 IMvigor011 trial and from Checkmate 274, with Professor Thomas Powles, lead PI of IMvigor011, joining the call. Live dial-in and webcast access are provided; a replay will be available at the company investor website.

Natera (NASDAQ: NTRA) announced that 14 studies featuring its Signatera ctDNA/MRD technology will be presented at the ESMO Congress, Oct 17–21, 2025 in Berlin, including six oral presentations. The IMvigor011 trial (Genentech/Roche) was selected for a Presidential Symposium on Oct 20; topline results were reported in August and the oral will include additional data on Signatera’s prediction of disease-free survival (DFS) and overall survival (OS) benefit from adjuvant atezolizumab in muscle-invasive bladder cancer (MIBC).

Key disclosed data: CheckMate 274 MRD analysis showed DFS for Signatera-positive patients treated with nivolumab of 7.4 months vs 2.8 months for placebo (HR: 0.35), while Signatera-negative patients showed no significant DFS improvement. Multiple other oral presentations cover colorectal, breast, renal, lung, and early cancer detection studies.

Natera (NASDAQ: NTRA) has reached a significant milestone in its EXPAND clinical trial, with enrollment exceeding 1,600 patients. The trial evaluates Fetal Focus™, a single gene noninvasive prenatal test (NIPT) for inherited conditions.

Initial results from EXPAND demonstrated 91% sensitivity, successfully identifying all 5 cases of homozygous variants. The trial, initiated in 2023, is distinguished by its comprehensive validation approach, confirming both positive and negative results through diagnostic testing.

Fetal Focus™ serves as an alternative testing option when biological fathers are unavailable for carrier testing, though testing both partners remains the gold standard. Natera expects to report comprehensive trial analysis in Q4 2025.

Natera (NASDAQ: NTRA) has published a groundbreaking study in the Journal of Clinical Oncology - Precision Oncology validating its Signatera™ test for testicular cancer. The multi-institutional study, analyzing 324 plasma samples from 74 patients, demonstrated that Signatera significantly outperformed standard serum tumor markers (STM) in predicting patient outcomes.

The study revealed impressive detection rates with Signatera showing 91.6% positivity for stage I and 100% for stages II and III. Notably, Signatera-positive patients showed significantly shorter event-free survival compared to Signatera-negative patients, with a hazard ratio of 12.45 (p<0.0001) during surveillance, while conventional STMs failed to show significant correlation with outcomes.